Eli Lilly and Co（LLY）の株式分析LLYEli Lilly and Co

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly and Co (LLY) is a good buy right now due to its strong recent performance, with a current price of $1273.46 and a year-to-date change of +17.87%. The company reported a remarkable Q2 revenue surge of 48% year-over-year to $23 billion, driven by strong sales of its products, particularly Mounjaro and Zepbound. Additionally, the forward P/E ratio of 24.39 indicates reasonable growth expectations compared to its current price. However, a key risk is the analyst target of $940, suggesting a potential downside of approximately 26.1% from the current price. Overall, the strong revenue growth and solid product pipeline make LLY an attractive long-term investment despite the noted risks.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.